Alerts will be sent to your verified email
Verify EmailEMCURE
Emcure Pharma
|
Natco Pharma
|
Concord Biotech
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
102.0 . | 58.0 . | 20.0 . |
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
4.66 % | 7.6 % | 2.26 % |
Financials
|
|||
5 yr Average ROE
|
18.62 % | 13.06 % | 20.02 % |
5yr average Equity Multiplier
|
2.84 | 1.18 | 1.26 |
5yr Average Asset Turnover Ratio
|
0.91 | 0.46 | 0.52 |
5yr Avg Net Profit Margin
|
7.16 % | 23.09 % | 30.81 % |
Price to Book
|
5.39 | 3.21 | 14.7 |
P/E
|
44.58 | 11.79 | 71.31 |
5yr Avg Cash Conversion Cycle
|
-21.19 Days | 10.54 Days | 37.41 Days |
Inventory Days
|
82.48 Days | 99.95 Days | 80.96 Days |
Days Receivable
|
94.32 Days | 86.16 Days | 111.87 Days |
Days Payable
|
169.53 Days | 154.15 Days | 173.13 Days |
5yr Average Interest Coverage Ratio
|
4.17 | 46.61 | 137.55 |
5yr Avg ROCE
|
26.51 % | 16.05 % | 25.59 % |
5yr Avg Operating Profit Margin
|
19.04 % | 30.17 % | 42.97 % |
5 yr average Debt to Equity
|
0.95 | 0.06 | 0.04 |
5yr CAGR Net Profit
|
42.9 % | 24.68 % | 12.77 % |
5yr Average Return on Assets
|
6.6 % | 11.07 % | 15.93 % |
Shareholdings
|
|||
Promoter Holding
|
77.94 % | 49.62 % | 44.08 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.14 % | 0.76 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
-0.2 % | -7.15 % | -0.72 % |
Emcure Pharma
|
Natco Pharma
|
Concord Biotech
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|